Title : Kidney and heart failure outcomes associated with SGLT2 inhibitor use.

Pub. Date : 2022 May

PMID : 35145275






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 After observations that sodium-glucose co-transporter 2 (SGLT2) inhibitors - originally developed as glucose-lowering agents - improved cardiovascular and renal outcomes in patients with type 2 diabetes, dedicated trials were initiated to evaluate the cardiovascular and kidney protective effects in patients with CKD or heart failure. Glucose solute carrier family 5 member 2 Homo sapiens
2 After observations that sodium-glucose co-transporter 2 (SGLT2) inhibitors - originally developed as glucose-lowering agents - improved cardiovascular and renal outcomes in patients with type 2 diabetes, dedicated trials were initiated to evaluate the cardiovascular and kidney protective effects in patients with CKD or heart failure. Glucose solute carrier family 5 member 2 Homo sapiens